Tag Archives: Rejuva

STEP UP Wegovy HD Data; New Novo Obesity + T1DM Study; Fractyl Q1 ’26 Earnings and CTA Authorization of RJVA-001; Roche 2026 Diagnostics Day

A series of cardiometabolic-related news items has been observed from Novo Nordisk, Fractyl Health, and Roche. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Novo Triple Agonist T2DM Data; BI 2026 Annual Press Conference; Pfizer Doses First Patient in VESPER-5; Merck Acquires Terns; Fractyl Q4 ’25 Earnings; Biomea FY 2025 Updates; BrightGene Ph1 Dual Agonist Data

A series of cardiometabolic-related news items has been observed by Novo Nordisk, Boehringer Ingelheim, Pfizer, Merck, Fractyl Health, Biomea Fusion, and BrightGene Bio-Medical Technology. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Novo Partners with Septerna for Obesity Drug Development; GSK Acquires MASH Asset from Boston Pharma; Sernova Interim Cell Pouch Results; Found Integrates with LillyDirect and NovoCare; Cytokinetics Ph3 HCM Results; Lexicon, Fractyl, and Scholar Rock Q1 ’25 Earnings

A series of cardiometabolic-related news items has been observed from: Novo Nordisk/Septerna, GSK/Boston Pharmaceuticals, Sernova Biotherapeutics, Found, Cytokinetics, Lexicon Pharmaceuticals, Fractyl Health, and Scholar Rock. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Novartis and Biocon Q4 ’24 Earnings; Metsera and Beta Bionics IPO Updates; Fractyl Business Updates

A series of cardiometabolic-related news items have been observed by Novartis, Metsera, Beta Bionics, Biocon, and Fractyl Health. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

New Zepbound DTC Observed; New Novo Insulin Trial; Amgen Damage Control; Lexicon, Fractyl, and Terns Q3 ‘24 Earnings; Metsera Series B Financing; G&L Oral GLP-1RA Data

A series of cardiometabolic-related news items have been observed from Lilly, Novo Nordisk, Amgen, Lexicon Pharmaceuticals, Fractyl Health, Terns Pharmaceuticals, Metsera, and Gan & Lee. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Medicare Price Negotiations; Lilly Targets HCPs Promoting Compounded GLP-1RAs; Arrowhead to Advance Obesity Pipeline; New AZ Ph2 Oral GLP-1RA Obesity Trial; Rivus Ph2 HFpEF Topline Results; Zealand and Fractyl Q2 ’24 Earnings Updates

A series of cardiometabolic-related news items have been observed from CMS, Lilly, Zealand, AstraZeneca, Fractyl Health, and Rivus Pharmaceuticals. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Ionis’s Olezarsen FCS Filing Accepted with Priority Review; Scholar Rock Obesity Development Updates; Zealand Raises $900M Towards Obesity Development; Sernova Ph1/2 Cell Pouch T1DM Updates; Fractyl Pipeline Updates; New Dario Digital Health GLP-1RA Data

A series of cardiometabolic-related news items have been observed from Ionis, Scholar Rock, Zealand, Sernova, Fractyl Health, and Dario Health. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

ADA 2024 Key Press Releases (June 23)

On the third day of ADA 2024, four cardiometabolic-related news items have been observed from Senseonics, Altimmune, Fractyl Health, and Gan & Lee. Below, FENIX provides context and analysis for the announcements.

This content is for Read Less members only.

Already a member? Log in here

Fractyl Q1 ’24 Earnings; 89bio Initiates Ph3 ENLIGHTEN-Cirrhosis; USPTO Extends Bempedoic Acid Patent; Inpefa HFpEF Post-Hoc Analysis

A series of cardiometabolic-related news items have been observed from Fractyl Health, 89bio, Esperion, and Lexicon. Below, FENIX provides highlights and insight for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Biomea and Fractyl Q4 ’23 Earnings; Glucotrack Implantable CGM Update; Costco Weight Loss Program; D&D Fast Track Designation in MASH; New Aligos Ph2a MASH Trial; Sernova Cell Pouch Updates

A series of cardiometabolic-related news items have been observed from Biomea Fusion, Fractyl Health, Glucotrack, Sesame/Costco, D&D Pharmatech, Aligos Therapeutics, and Sernova. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here